Heron Therapeutics vs Nuvation Bio
HRTX and NUVB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HRTX and NUVB compare
Nuvation Bio is the larger company, worth 24 times as much as Heron Therapeutics ($1.4B against $58.9M).
Nuvation Bio grew revenue faster over the last twelve months (654% versus −4.4% for Heron Therapeutics).
Heron Therapeutics keeps more of each dollar of sales as profit, with a net margin of −14.5% compared with −67.4% at Nuvation Bio.
Heron Therapeutics scores higher on the StockData Score (8 against 4 for Nuvation Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HRTX | NUVB |
|---|---|---|
| Size and price | ||
| Market cap | $58.9M | $1.4B |
| Share price | $0.310 | $3.99 |
| Change, 1 year | −72.0% | −19.1% |
| Change, 5 years | −96.9% | −55.9% |
| Beta (5Y) | 1.79 | 1.45 |
| Employees | 128 | 298 |
| StockData Score | ||
| Total score | 8 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.4× (better) | 6.9× |
| P/B | 12.0× | 6.1× (better) |
| FCF yield | −24.4% | – |
| Fair value | – | $1.94 |
| Margin of safety | – | −105% |
| Growth | ||
| Revenue growth (TTM) | −4.4% | 654% (better) |
| Revenue growth, 5Y average | 11.8% | – |
| Profitability | ||
| Gross margin | 71.5% | – |
| Operating margin | −5.7% (better) | −61.2% |
| Net margin | −14.5% (better) | −67.4% |
| FCF margin | −9.7% | – |
| Return on equity | −218% | −49.1% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.03 (better) |
| Interest coverage | – | −5.9× |
| Current ratio | 2.33 | 7.45 (better) |
| Altman Z-score | −10.60 | 0.06 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 70.4% | 66.5% |
| Held by insiders | 21.6% | 24.6% |
| Insider net buying, 12 months | – | −$4.5M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 22.8% | 23.4% |
Go deeper
- HRTX stock overview
- HRTX income statement
- HRTX valuation and score
- NUVB stock overview
- NUVB income statement
- NUVB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.